Tìm theo
Moclobemide
Các tên gọi khác (12 ) :
  • 4-Chlor-N-(2-morpholinoethyl)benzamid
  • 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide
  • 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide
  • Aurorix
  • Moclaime
  • Moclamide
  • Moclamine
  • Moclobemid
  • Moclobemida
  • Moclobemide
  • Moclobemidum
  • p-Chloro-N-(2-morpholinoethyl)benzamide
antidepressive agents, monoamine oxidase inhibitors
Thuốc Gốc
Small Molecule
CAS: 71320-77-9
ATC: N06AG02
CTHH: C13H17ClN2O2
PTK: 268.739
A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C13H17ClN2O2
Phân tử khối
268.739
Monoisotopic mass
268.097855505
InChI
InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)
InChI Key
InChIKey=YHXISWVBGDMDLQ-UHFFFAOYSA-N
IUPAC Name
4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide
Traditional IUPAC Name
moclobemide
SMILES
ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1
Độ hòa tan
1.12e+00 g/l
logP
1.5
logS
-2.4
pKa (strongest acidic)
14.73
pKa (Strongest Basic)
6.02
PSA
41.57 Å2
Refractivity
71.93 m3·mol-1
Polarizability
28.28 Å3
Rotatable Bond Count
4
H Bond Acceptor Count
3
H Bond Donor Count
1
Physiological Charge
0
Number of Rings
2
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Dược Lực Học : Moclobemide belongs to a class of MAOI antidepressants known as reversible inhibitors of monoamine oxidase type-A (RIMAs). The primary role of monoamine oxidase MAO lies in the metabolism of and regulation of the levels of monoamines (serotonin, norepinephrine, and dopamine). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms. RIMAs demonstrate transient inhibition of the substrate binding site of MAO-A as well as competitive displacement from this site by bioamines. The RIMAs are distinguished from the older monoamine oxidase inhibitors (MAOIs) by their selectivity and reversibility.
Cơ Chế Tác Dụng : A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder. The mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms.
Dược Động Học :
▧ Absorption :
Well absorbed from the gastrointestinal tract (> 95%). The presence of food reduces the rate but not the extent of absorption. Hepatic first pass metabolism reduces bioavailability to 45-70% following administration of a single dose, but increases to 80% with multiple dosing as a result of saturation of the first pass effect. Peak plasma concentrations are reached within 1 - 2 hours following oral administration.
▧ Protein binding :
Approximately 50% (primarily to albumin)
▧ Metabolism :
Moclobemide is almost completely metabolized in the liver by Cytochrome P450 2C19 and 2D6.
▧ Half Life :
1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted
Độc Tính : LD50 (mouse) is 730mg/kg and LD50 (rat) is 1,300mg/kg. Signs of toxicity include hypertension, drowsiness, dizziness, confusion, tremors, headache, agitation, muscle rigidity and seizures.
Chỉ Định : For the treatment of depression.
Tương Tác Thuốc :
  • Amitriptyline Possible severe adverse reaction with this combination
  • Amoxapine Possible severe adverse reaction with this combination
  • Bezafibrate MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like moclobemide.
  • Brimonidine MAO Inhibitors like moclobemide may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
  • Buprenorphine Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like moclobemide. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
  • Cimetidine Cimetidine may increase the serum concentration of moclobemide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of moclobemide if cimetidine is initiated, discontinued or dose changed.
  • Citalopram Possible serotoninergic syndrome
  • Clomipramine Possible severe adverse reaction with this combination
  • Desipramine Possible severe adverse reaction with this combination
  • Desvenlafaxine Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
  • Dextromethorphan Increased CNS toxicity
  • Dobutamine Moclobemide increases the sympathomimetic effect of dobutamine.
  • Donepezil Possible antagonism of action
  • Dopamine Moclobemide increases the sympathomimetic effect of dopamine.
  • Doxepin Possible severe adverse reaction with this combination
  • Ephedra Moclobemide increases the sympathomimetic effect of ephedra.
  • Ephedrine Moclobemide increases the sympathomimetic effect of ephedrine.
  • Epinephrine Moclobemide increases the sympathomimetic effect of epinephrine.
  • Fenoterol Moclobemide increases the sympathomimetic effect of fenoterol.
  • Fluoxetine Risk of serotoninergic syndrome
  • Fluvoxamine Increased incidence of adverse effects with this association
  • Galantamine Possible antagonism of action
  • Imipramine Possible severe adverse reaction with this combination
  • Isoprenaline Moclobemide increases the sympathomimetic effect of isoproterenol.
  • Mephentermine Moclobemide increases the sympathomimetic effect of mephentermine.
  • Metaraminol Moclobemide increases the sympathomimetic effect of metaraminol.
  • Methoxamine Moclobemide increases the sympathomimetic effect of methoxamine.
  • Milnacipran Increase serotonin levels. Combination therapy is contraindicated.
  • Norepinephrine Moclobemide increases the sympathomimetic effect of norepinephrine.
  • Nortriptyline Possible severe adverse reaction with this combination
  • Orciprenaline Moclobemide increases the sympathomimetic effect of orciprenaline.
  • Paroxetine Possible severe adverse reaction with this combination
  • Pethidine Increased CNS toxicity (can cause death)
  • Phenylephrine Moclobemide increases the sympathomimetic effect of phenylephrine.
  • Phenylpropanolamine Moclobemide increases the sympathomimetic effect of phenylpropanolamine.
  • Pirbuterol Moclobemide increases the sympathomimetic effect of pirbuterol.
  • Procaterol Moclobemide increases the sympathomimetic effect of procaterol.
  • Protriptyline Possible severe adverse reaction with this combination
  • Pseudoephedrine Moclobemide increases the sympathomimetic effect of pseudoephedrine.
  • Rivastigmine Possible antagonism of action
  • Rizatriptan The MAO inhibitor, moclobemide, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated.
  • Salbutamol Moclobemide increases the sympathomimetic effect of salbutamol.
  • Selegiline Decrease in selectivity
  • Sertraline Possible severe adverse reaction with this combination
  • Sibutramine Possible serotoninergic syndrome with this combination
  • Tacrine The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Moclobemide, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
  • Terbinafine Terbinafine may reduce the metabolism and clearance of Moclobemide. Consider alternate therapy or monitor for therapeutic/adverse effects of Moclobemide if Terbinafine is initiated, discontinued or dose changed.
  • Terbutaline Moclobemide increases the sympathomimetic effect of terbutaline.
  • Tetrabenazine Tetrabenazine may increase the adverse/toxic effects of Moclobemide. Concomitant therapy is contraindicated.
  • Ticlopidine Ticlopidine may decrease the metabolism and clearance of Moclobemide. Consider alternate therapy or monitor for adverse/toxic effects of Moclobemide if Ticlopidine is initiated, discontinued or dose changed.
  • Tolcapone Tolcapone and Moclobemide decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
  • Tramadol Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, moclobemide.
  • Tranylcypromine Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
  • Trazodone Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
  • Trimethobenzamide Trimethobenzamide and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
  • Trimipramine Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
  • Triprolidine Triprolidine and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
  • Trospium Trospium and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
  • Tryptophanyl-5'amp Possible severe adverse reaction with this combination
  • Venlafaxine Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
  • Zolmitriptan The MAO inhibitor, moclobemide, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing moclobemide are contraindicated.
Liều Lượng & Cách Dùng : Tablet - Oral
Tablet - Oral
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Aurorix
  • Công ty :
    Sản phẩm biệt dược : Manerix
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB01171
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=4235
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46504667
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D02561
ChemSpider
http://www.chemspider.com/Chemical-Structure.4087.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15613
PharmGKB
http://www.pharmgkb.org/drug/PA452615
Wikipedia
http://en.wikipedia.org/wiki/Moclobemide
... loading
... loading